Citigroup analyst Stephanie Davis maintained a Buy rating on Tabula Rasa HealthCare (NASDAQ: TRHC) today and set a price target of $76. The company’s shares closed yesterday at $64.43, close to its 52-week high of $70.15.
Davis has an average return of 67.2% when recommending Tabula Rasa HealthCare.
According to TipRanks.com, Davis is ranked #1117 out of 4850 analysts.
Tabula Rasa HealthCare has an analyst consensus of Strong Buy, with a price target consensus of $70.50, a 9.4% upside from current levels. In a report issued on August 7, Robert W. Baird also reiterated a Buy rating on the stock with a $70 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $70.15 and a one-year low of $16.72. Currently, Tabula Rasa HealthCare has an average volume of 343.1K.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tabula Rasa Healthcare, Inc. engages in the development of pharmaceutical software that optimizes medication regimens. It offers cloud-based applications, such as EireneRx and MedWise Advisor. The company was founded by Calvin H. Knowlton and Orsula V. Knowlton in April 2009 and is headquartered in Moorestown, NJ.
